Business Wire

NY-ESTÉE-LAUDER

Share
The Estée Lauder Companies Appoints Meridith Webster as Executive Vice President, Global Communications and Public Affairs

The Estée Lauder Companies Inc. (NYSE:EL) announced today that Meridith Webster will join the company in the newly-created role of Executive Vice President, Global Communications and Public Affairs , effective May 17, 2021. Meridith will report jointly to William P. Lauder, Executive Chairman, and Fabrizio Freda, President and Chief Executive Officer. She will also join The Estée Lauder Companies Inc.’s (“ELC”) Executive Leadership Team.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005345/en/

Meridith will succeed Alexandra (Alex) Trower as head of Global Communications and Maria Cristina (MC) González Noguera as head of Global Public Affairs. Her appointment follows the news that Alex has made the decision to retire in June after an esteemed career at the company, and that MC was recently tapped for the role of EVP and Chief Communications and Public Affairs Officer at Popular Inc., the Puerto Rico-based global financial services conglomerate.

“Our world-class Global Communications and Public Affairs teams have consistently advanced ahead of the curve against the backdrop of an increasingly complex and rapidly-changing global landscape,” said Fabrizio Freda . “Meridith’s appointment will continue to enable and enhance our delivery of thoughtful, effective communications to our valued global stakeholders as she leads these talented teams to new heights.”

“Meridith’s deep public and private sector experience, coupled with her core values and leadership style, make her uniquely suited to step into this role now,” said William P. Lauder . “I am so proud of the incredible work of our Global Communications and Public Affairs teams and I know they will be in great hands under Meridith’s leadership as she joins our ELC family.”

In this new role, Meridith will lead ELC’s global communications and public affairs strategic agendas to advance and protect its business interests and corporate reputation globally, and strengthen relationships to drive value for key stakeholders. She will serve as a strategic advisor to the ELC’s Executive Leadership Team, the Board of Directors and the Lauder Family on a variety of critical topics.

Meridith will oversee ELC’s Global Communications and Public Affairs teams, elevating the impact of these important functions across the business. She will lead the strategy and delivery of holistic, integrated global communications to advance ELC’s corporate reputation and winning business narrative, while building brand equity and strengthening the platforms that resonate with key audiences internally and externally. She will also lead the global public affairs and stakeholder engagement strategy to further advance ELC’s business goals, build reputation capital and proactively mitigate issues.

Meridith’s deep government experience includes tenures under multiple U.S. presidential administrations. Meridith joins ELC from the Biden White House, where she served as Special Assistant to the President and Chief of Staff to the Domestic Policy Council. At the Obama White House, she served as Senior Advisor to two White House Chiefs of Staff, Rahm Emanuel and Pete Rouse. She also served as Deputy Chief of Staff to Susan Rice, then the U.S. Ambassador to the United Nations. Meridith started her career working at the Clinton White House and the U.S. State Department before earning her J.D. Degree at Georgetown University Law Center.

Prior to serving in the Biden Administration, she served as Vox Media’s first-ever Chief Communications Officer, overseeing strategic and crisis communications and media relations across a growing modern media company, including editorial networks and advertising, studios, and podcasting. She also previously led the Public Affairs practice at Emerson Collective and served as Global Head of Public Affairs at Bloomberg L.P. and Bloomberg Philanthropies where she managed the expansion of the business and established public affairs and communications functions in Washington, New York and globally.

“I am thrilled to be joining The Estée Lauder Companies. Alex and MC each have done a terrific job leading the company’s Global Communications and Public Affairs functions and positioning these talented teams as strategic business partners,” said Meridith Webster . “It is an honor to step into this new role and I am excited to continue building on the successes of these teams in a rapidly-evolving space. I look forward to partnering with Fabrizio, William and the entire Executive Leadership Team to drive the overall success and continued growth of ELC.”

About The Estée Lauder Companies Inc.

The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, TOM FORD BEAUTY, Smashbox, Ermenegildo Zegna, AERIN, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, BECCA, Too Faced and Dr. Jart+.

ELC-C
ELC-L

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release

- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c

Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release

Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye